Fresh analysis indicates that people who discontinue new slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt conventional diet and exercise programs.
Research printed in a prominent health publication demonstrates that while overweight people often shed substantial amounts of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these drugs must be aware of the risk of rapid rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to starting mass in about a year and a half.
Analyzing Treatments
The study, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
Scientists emphasize that individuals who shed pounds through dieting typically have a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Doctors suggest the mechanism of the drugs accounts for the heightened weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone levels far above than normal might result in the body to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to hunger is no longer kept in check, making binge eating much more probable."
A Chronic Condition?
The NHS suggest the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts contend that, given the likelihood of weight regain, the therapy might need to be life-long.
This perspective is supported by drug manufacturers, who state that the results "underscore the chronic nature of obesity," comparing it to managing conditions like high blood pressure.
User Experiences
Individuals who have come off the medication explain a sudden resurgence of hunger.
"It felt as if a trigger flipping and I was suddenly ravenous," described one woman.
This challenge is compounded if users have not established lasting dietary or behavioural modifications during therapy.
Widespread Interest
Figures show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Use is more common among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, clinicians emphasize that while the jabs are effective tools for weight loss, they are not a standalone solution and long-term success hinges on combined behavioural support.
